Degeneration of the cerebellum causes ataxia, a disorder of balance and coordination which can be severely disabling and render afflicted individuals unable to walk, speak, or make coordinated movements. Genetic ataxia affects half a million people worldwide, but current testing only identifies roughly 50% of the responsible genes. Better diagnosis will lead to better treatment and uncovering novel disease genes could provide new insight into the workings of the cerebellum and suggest ways to combat its degeneration. New technology, termed next-generation sequencing, is a cost-effective means of examining either the entire human genome or the key portion that codes for protein, known as the exome, and can be used to comprehensively investigate patients for novel genetic mutations. The UCLA Ataxia and Neurogenetics Program possesses a unique resource for studying this genetic variation with a large bank of DNA samples from hundreds of individuals and families with cerebellar ataxia, all with precisely detailed clinical information. 1) We will examine the exomes of 20 ataxic families with dominant (10) or recessive (10) inheritance, all screened negative for the most common known genetic ataxias. We will initially confirm probands possess no variants in rare (<1% worldwide) ataxia genes and then proceed to identifying novel causative variants. We have developed a pipeline for excluding benign polymorphisms and isolating only those variants with the highest probability of causing neurologic disease. For patients and families remaining unidentified following this analysis, we will examine their genomes for disease-causing variants potentially altering gene expression and/or regulation. We will estimate the occurrence of mutations in genes we discover within our ataxia patient population and confirm that they are not found in normal individuals. 2) Although examination of families is essential to the identification of new disease genes, the majority of undiagnosed patients seen in ataxia clinics lack a clearly defined family history of disease. To address these individuals, we will examine subgroups of patients with similar detailed clinical presentations as they will be most likely to share common genetic causes. We will initially apply our analysis pipeline across a specific well- defined subtype of pure cerebellar ataxia to isolate potential disease-causing genes and mutations. 3) Lastly, we will screen identified variants in a cell culture system using human neurons with a variety of tests designed to quantitate the severity of the mutations on basic cellular functioning. This information will be used to characterize and prioritize variants of unknown clinical significance for further detailed analysis. In summary, this study will provide a comprehensive view of the genetic etiologies behind cerebellar ataxia, define new molecular pathways important to the normal function of the cerebellum, contribute to advancements in clinical diagnosis, and help elucidate the mechanisms causing degenerative ataxia.

Public Health Relevance

Genetic ataxia affects over half a million people worldwide, causing severe movement and balance problems due to degeneration of the cerebellum, yet in more than half of these patients, the defective gene remains unknown. At UCLA we have collected DNA from hundreds of patients and families with unknown ataxia and, using this unique clinical resource, we will identify novel disease-causing mutations by employing next- generation sequencing technology to rapidly examine all the genes in these patient's genomes. This work will aid diagnosis by identifying new mutations and novel ataxia genes, improve our knowledge of molecular pathways important to normal cerebellar function, and lend insight into the development of this devastating neurological disease.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Genetics of Health and Disease Study Section (GHD)
Program Officer
Gwinn, Katrina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Ramos, Eliana Marisa; Carecchio, Miryam; Lemos, Roberta et al. (2018) Primary brain calcification: an international study reporting novel variants and associated phenotypes. Eur J Hum Genet 26:1462-1477
Fan, Judy; Fogel, Brent L (2018) Successful treatment of a genetic childhood ataxia due to riboflavin transporter deficiency. Cerebellum Ataxias 5:12
Fogel, Brent L (2018) Collaborative science unites researchers and a novel spastic ataxia gene. Ann Neurol 83:1072-1074
Zambonin, Jessica L; Bellomo, Allison; Ben-Pazi, Hilla et al. (2017) Spinocerebellar ataxia type 29 due to mutations in ITPR1: a case series and review of this emerging congenital ataxia. Orphanet J Rare Dis 12:121
Wolf, Susan M; Thyagarajan, Bharat; Fogel, Brent L (2017) The need to develop a patient-centered precision medicine model for adults with chronic disability. Expert Rev Mol Diagn 17:415-418
Fogel, Brent L; Lee, Hane; Strom, Samuel P et al. (2016) Clinical exome sequencing in neurogenetic and neuropsychiatric disorders. Ann N Y Acad Sci 1366:49-60
Berto, Stefano; Usui, Noriyoshi; Konopka, Genevieve et al. (2016) ELAVL2-regulated transcriptional and splicing networks in human neurons link neurodevelopment and autism. Hum Mol Genet 25:2451-2464
Vanderver, Adeline; Simons, Cas; Helman, Guy et al. (2016) Whole exome sequencing in patients with white matter abnormalities. Ann Neurol 79:1031-1037
Fogel, Brent L; Satya-Murti, Saty; Cohen, Bruce H (2016) Clinical exome sequencing in neurologic disease. Neurol Clin Pract 6:164-176
Aranca, Tanya V; Jones, Tracy M; Shaw, Jessica D et al. (2016) Emerging therapies in Friedreich's ataxia. Neurodegener Dis Manag 6:49-65

Showing the most recent 10 out of 17 publications